Pharmaceutical Contract Development and Manufacturing Market - Trends Forecast Till 2028

Market Overview

Global Pharmaceutical Contract Development and Manufacturing market is anticipated to reach USD 103.8 billion in 2021 growing at a CAGR of 7.9% during the forecasting period, 2021-2028.

Contract manufacturing in pharmaceutical industry are term used companies that provide the services of drug manufacturing and others and work on contact basis. They don’t brand their name that is they work under the label/branding of the other company. They are unable to buy the raw material (due to its heavy price) used and thus on contract basis they are able to get the raw material and are able to process it to make chemicals. The brands are thus also able to outsource their work.

With an increased research in the pharmaceutical sector along with patent expiry and an increased demand for generic medicine are some of the factors that have supported long-term expansion for the Pharmaceutical Contract Development and Manufacturing industry.

Key Findings

Global Pharmaceutical Contract Development and Manufacturing market is segmented into Pharmaceutical, Biologics, Active Pharma ingredients, tablet, Parenteral, Oral Liquid, Semi-Solids, end-user and geography.

The end-User segment is segmented into Big Pharma, Small Pharma, Generic Pharma, CRO

Geographically, the global Pharmaceutical Contract Development and Manufacturing market is sub-segmented into North America, Europe, Asia-Pacific, Middle East and Africa and South America and insights are provided for each region and major countries within the regions

Competitive Landscape

Key players in the global Pharmaceutical Contract Development and Manufacturing market are Thermo Fisher Scientific Inc. (US), Catalent, Inc. (US), Lonza Group Ltd. (Switzerland), Recipharm AB (Sweden), Vetter Pharma International GmbH (Germany), FAMAR Health Care Services (France), AbbVie Inc. (US), Aenova Group (Germany), Almac Group (UK), Siegfried Holding AG (Switzerland), Evonik Industries AG (Germany), WuXi AppTec (China), Samsung BioLogics (South Korea), Boehringer Ingelheim International GmbH (Germany), Cambrex Corporation (US), CordenPharma International (Germany), Albany Molecular Research Inc. (AMRI) (US), FUJIFILM Corporation (Japan), Piramal Pharma Solutions (India), Baxter International Inc. (US), Eurofins Scientific (Germany), BioVectra (Canada), Jubilant Life Science (India), NextPharma (UK), and Delpharm (France) among others.

Reasons to Acquire

• Increase your understanding of the market for identifying the best and suitable strategies and decisions on the basis of sales or revenue fluctuations in terms of volume and value, distribution chain analysis, market trends and factors
• Gain authentic and granular data access for Pharmaceutical Contract Development and Manufacturing market so as to understand the trends and the factors involved behind changing market situations
• Qualitative and quantitative data utilization to discover arrays of future growth from the market trends of leaders to market visionaries and then recognize the significant areas to compete in the future
• In-depth analysis of the changing trends of the market by visualizing the historic and forecast year growth patterns

Report Scope